Petros Pharma Appoints New CMO, Elects Director
Ticker: PTPI · Form: 8-K · Filed: Oct 4, 2024 · CIK: 1815903
| Field | Detail |
|---|---|
| Company | Petros Pharmaceuticals, Inc. (PTPI) |
| Form Type | 8-K |
| Filed Date | Oct 4, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, personnel
TL;DR
Petros Pharma beefs up exec team with new CMO and board member.
AI Summary
Petros Pharmaceuticals, Inc. announced on October 1, 2024, the appointment of Dr. Fady Malik as Chief Medical Officer and the election of Ms. Jennifer Choe to its Board of Directors. Dr. Malik will lead the company's clinical development and regulatory affairs, while Ms. Choe brings extensive experience in the pharmaceutical industry to the board.
Why It Matters
The appointment of a new Chief Medical Officer and a director with relevant industry experience could signal a strategic shift or renewed focus on clinical development and governance for Petros Pharmaceuticals.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Petros Pharmaceuticals, Inc. (company) — Registrant
- Dr. Fady Malik (person) — Appointed Chief Medical Officer
- Ms. Jennifer Choe (person) — Elected to Board of Directors
- October 1, 2024 (date) — Date of earliest event reported
FAQ
What is the primary responsibility of the newly appointed Chief Medical Officer, Dr. Fady Malik?
Dr. Fady Malik will lead Petros Pharmaceuticals' clinical development and regulatory affairs.
What is the background of the newly elected Board of Directors member, Ms. Jennifer Choe?
Ms. Jennifer Choe brings extensive experience in the pharmaceutical industry.
On what date did these changes at Petros Pharmaceuticals become effective?
The earliest event reported is dated October 1, 2024.
What is the principal executive office address for Petros Pharmaceuticals?
The principal executive offices are located at 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036.
What is the Commission File Number for Petros Pharmaceuticals?
The Commission File Number for Petros Pharmaceuticals is 001-39752.
Filing Stats: 538 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-10-04 17:15:45
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PTPI The Nasdaq Stock Marke
Filing Documents
- tm2425618d1_8k.htm (8-K) — 22KB
- 0001104659-24-106322.txt ( ) — 192KB
- ptpi-20241001.xsd (EX-101.SCH) — 3KB
- ptpi-20241001_lab.xml (EX-101.LAB) — 33KB
- ptpi-20241001_pre.xml (EX-101.PRE) — 22KB
- tm2425618d1_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 1, 2024, John Shulman, who served as a member of the board of directors (the "Board") of Petros Pharmaceuticals, Inc. (the "Company"), tendered his resignation from his role as director of the Company, effective as of October 1, 2024. Mr. Shulman's resignation from the Board was not in connection with any disagreement between Mr. Shulman and the Company, its management, the Board or any committee of the Board on any matter relating to the Company's operations, policies or practices, or any other matter. On October 2, 2024, Greg Bradley, who served as a member of the Board tendered his resignation from his role as director of the Company, effective as of October 2, 2024. Mr. Bradley's resignation from the Board was not in connection with any disagreement between Mr. Bradley and the Company, its management, the Board or any committee of the Board on any matter relating to the Company's operations, policies or practices, or any other matter.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PETROS PHARMACEUTICALS, INC. Date: October 4, 2024 By: /s/ Fady Boctor Name: Fady Boctor Title: President and Chief Commercial Officer